Ginkgo Bioworks (NYSE:DNA) Posts Earnings Results, Misses Expectations By $0.37 EPS

Ginkgo Bioworks (NYSE:DNA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.45) by ($0.37), Zacks reports. The business had revenue of $43.85 million during the quarter, compared to the consensus estimate of $44.43 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Ginkgo Bioworks updated its FY 2025 guidance to EPS.

Ginkgo Bioworks Trading Down 5.2 %

Shares of Ginkgo Bioworks stock traded down $0.45 during mid-day trading on Friday, reaching $8.20. 2,260,857 shares of the stock were exchanged, compared to its average volume of 1,830,178. The company has a market capitalization of $471.04 million, a P/E ratio of -0.63 and a beta of 1.16. The company has a 50-day simple moving average of $11.49. Ginkgo Bioworks has a fifty-two week low of $5.26 and a fifty-two week high of $64.40.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.